0
2022
House Dust Mite Allergy Treatment Market

House Dust Mite Allergy Treatment Market

by Treatment (Antihistamine, Immunotherapy, Other), by Type (Prescription based drugs, Over the counter drugs), by Route of administration (Oral medication, Nasal administration), by Distribution channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy): Global Opportunity Analysis and Industry Forecast, 2021-2031

Report Code: A16570
Jun 2022 | Pages: 245
Tables: 172
Charts: 61
  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.

 

House Dust Mite Allergy Treatment Market Research, 2031

The global house dust mite allergy treatment market size was valued at $1.5 billion in 2021, and is projected to reach $5.2 billion by 2031, growing at a CAGR of 13.4% from 2022 to 2031.House dust mite allergy is caused by dust mites, which are microscopic, eight-legged creatures that resemble to white spider. House dust mite allergy causes symptoms such as hay fever, cough, runny nose, and itchy red watery eyes.

The COVID-19 outbreak is anticipated to have a positive impact on growth of the global house dust mite allergy treatment market. . The people were forced to stay at home for longer time, which increased the exposure to indoor allergens and pollutants. Thus, increase in cases of house dust mite allergy during the COVID-19 pandemic notably contribute toward the growth of the market.

The growth of the global house dust mite allergy treatment market size is majorly driven by increase in prevalence of allergic diseases associated with house dust mites, rise in demand for immunological products, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments, and rise in R&D activities for manufacturing of anti-allergy drugs. According to the one of the chief medical officers at Medscape Education, in 2020, it was reported that around 20 million Americans are allergic to house dust mite. In addition, according to the Journal of Scientific Report, in March 2022, house dust mite is one of the leading factors of airway allergic diseases.

House Dust Mite Allergy Treatment Market, House Dust Mite Allergy Treatment Market size, House Dust Mite Allergy Treatment Market share, House Dust Mite Allergy Treatment Market trends, House Dust Mite Allergy Treatment Market growth, House Dust Mite Allergy Treatment Market analysis, House Dust Mite Allergy Treatment Market forecast, House Dust Mite Allergy Treatment Market opportunity

Furthermore, increase in prevalence of asthma, house dust allergy and allergic rhinitis drives house dust mite allergy treatment market share. The population diagnosed asthma and allergic rhinitis is highly vulnerable to house dust mite allergy, thus driving the house dust mite allergy treatment market growth. In addition, increase in prevalence of indoor air pollutant such as house dust mites, pet dust, and pollens is anticipated to contribute toward the growth of the market. A person’s immune system reacts to allergens present in indoor such as dust mite, and develops allergic rhinitis. Moreover, increase in initiatives to spreading knowledge regarding different types of allergies propels the growth of the market

Furthermore, technological developments in the pharmaceutical industry to manufacture advanced anti-allergy products are expected to provide remunerative opportunities for expansion of the global house dust mite allergy treatment market during the house dust mite allergy treatment market forecast period. Moreover, strong presence of key manufacturing companies to manufacture and distribute house dust mite allergy treatment products and rise in expenditure on healthcare products propel the growth of the market. Initiatives taken by government and private organizations to develop pharmaceutical industry propel the growth of the market. However, rise in hygiene practices reduces the occurrence of house dust mite allergy, which, in turn, is expected to restrict the market growth.

Global House Dust Mite Allergy Treatment Market Segmentation

The house dust mite allergy treatment market is segmented into treatment, type, route of administration, distribution channel, and region. By treatment, the market is categorized into antihistamine, immunotherapy, and others. On the basis of type, it is divided into prescription-based drugs and over-the-counter drugs. Depending on route of administration, it is categorized into oral medication and nasal administration. By distribution channel, it is segregated into hospital pharmacy, online pharmacy, and retail pharmacy.

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

Segment Review

Depending on treatment, the others segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to advancements in R&D activities in the pharmaceutical sector and increase in number of key manufacturers. However, the antihistamine segment is expected to witness considerable growth during the forecast period, owing to increase in demand for antihistamine

House Dust Mite Allergy Treatment Market

By type, the prescription-based drugs segment was the major contributor in 2021, and is expected to maintain its lead during the forecast period, owing to increase in prevalence of house dust mite allergy diseases and initiatives taken by government & private organization to spread awareness about allergic disease.

However, the over-the-counter drugs segment is expected to witness considerable growth during the forecast period, owing to increase in demand for over-the-counter drugs and increase in number of approval for over-the-counter anti-allergic drugs.

House Dust Mite Allergy Treatment Market

On the basis of route of administration, the oral medication segment dominated the market in 2021, and this trend is expected to continue during the forecast period, owing to increase in preference for oral route of administration, rise in number of U.S. FDA approvals for drugs, and advancements in R&D activities in the pharmaceutical sector.

House Dust Mite Allergy Treatment Market

By distribution channel, the hospital pharmacy segment was the major contributor in 2021, and is expected to maintain its lead during the forecast period, owing to rise in prevalence of allergic diseases, surge in demand for monoclonal antibodies, and initiatives taken by government for advancement of hospital pharmacies.

However, the online pharmacy segment is expected to witness considerable growth during the forecast period, due to advancements in technology in the healthcare sector and rise in demand for remote services.

House Dust Mite Allergy Treatment Market

Europe garnered a major share in the house dust mite allergy treatment market in 2021, and is expected to continue to dominate during the forecast period, owing to rise in prevalence of asthma & allergic rhinitis, increase in number of in-house dust pollution, presence of key players, and development in increase in R&D activities in the pharmaceutical sector in the region.

However, Asia-Pacific is expected to register highest CAGR of 14.4% from 2022 to 2031, owing to increase in prevalence of house dust mite allergy diseases, rise in awareness about spreading knowledge regarding allergens, surge in healthcare expenditure, and rise in adoption of immunotherapy drugs for the treatment of house dust mite allergies.

The key players operating in the global house dust mite allergy treatment market include ALK-Abello A/S, Allergy Therapeutics PLC, Bayer AG, Catalent Pharma Solutions Limited, GlaxoSmithKline Plc., Johnson and Johnson, Merz Pharma GmbH an Co. KGaA, Sanofi, Seqirus UK Limited, and Shionogi & Co. Ltd.

House Dust Mite Allergy Treatment Market

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the house dust mite allergy treatment market analysis from 2021 to 2031 to identify the prevailing house dust mite allergy treatment market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the house dust mite allergy treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global house dust mite allergy treatment market trends, key players, market segments, application areas, and market growth strategies.

House Dust Mite Allergy Treatment Market Report Highlights

Aspects Details
By Treatment
  • Antihistamine
  • Immunotherapy
  • Other
By Type
  • Prescription based drugs
  • Over the counter drugs
By Route of administration
  • Oral medication
  • Nasal administration
By Distribution channel
  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, U.K., Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Australia, South Korea, Rest of Asia-Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players Shionogi and Co. Ltd., ALK Abello A S, Catalent Pharma Solutions Limited, GlaxoSmithKline plc., Merz Pharma GmbH an Co. KGaA, Seqirus UK Limited, johnson and johnson md&d, Sanofi, Bayer AG, Allergy Therapeutics PLC
 
  • CHAPTER 1:INTRODUCTION

    • 1.1.Report description

    • 1.2.Key market segments

    • 1.3.Key benefits to the stakeholders

    • 1.4.Research Methodology

      • 1.4.1.Secondary research

      • 1.4.2.Primary research

      • 1.4.3.Analyst tools and models

  • CHAPTER 2:EXECUTIVE SUMMARY

    • 2.1.Key findings of the study

    • 2.2.CXO Perspective

  • CHAPTER 3:MARKET OVERVIEW

    • 3.1.Market definition and scope

    • 3.2.Key findings

      • 3.2.1.Top investment pockets

    • 3.3.Porter’s five forces analysis

    • 3.4.Top player positioning

    • 3.5.Market dynamics

      • 3.5.1.Drivers

      • 3.5.2.Restraints

      • 3.5.3.Opportunities

    • 3.6.COVID-19 Impact Analysis on the market

  • CHAPTER 4: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT

    • 4.1 Overview

      • 4.1.1 Market size and forecast

    • 4.2 Antihistamine

      • 4.2.1 Key market trends, growth factors and opportunities

      • 4.2.2 Market size and forecast, by region

      • 4.2.3 Market analysis by country

    • 4.3 Immunotherapy

      • 4.3.1 Key market trends, growth factors and opportunities

      • 4.3.2 Market size and forecast, by region

      • 4.3.3 Market analysis by country

    • 4.4 Other

      • 4.4.1 Key market trends, growth factors and opportunities

      • 4.4.2 Market size and forecast, by region

      • 4.4.3 Market analysis by country

  • CHAPTER 5: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE

    • 5.1 Overview

      • 5.1.1 Market size and forecast

    • 5.2 Prescription based drugs

      • 5.2.1 Key market trends, growth factors and opportunities

      • 5.2.2 Market size and forecast, by region

      • 5.2.3 Market analysis by country

    • 5.3 Over the counter drugs

      • 5.3.1 Key market trends, growth factors and opportunities

      • 5.3.2 Market size and forecast, by region

      • 5.3.3 Market analysis by country

  • CHAPTER 6: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

    • 6.1 Overview

      • 6.1.1 Market size and forecast

    • 6.2 Oral medication

      • 6.2.1 Key market trends, growth factors and opportunities

      • 6.2.2 Market size and forecast, by region

      • 6.2.3 Market analysis by country

    • 6.3 Nasal administration

      • 6.3.1 Key market trends, growth factors and opportunities

      • 6.3.2 Market size and forecast, by region

      • 6.3.3 Market analysis by country

  • CHAPTER 7: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL

    • 7.1 Overview

      • 7.1.1 Market size and forecast

    • 7.2 Hospital Pharmacy

      • 7.2.1 Key market trends, growth factors and opportunities

      • 7.2.2 Market size and forecast, by region

      • 7.2.3 Market analysis by country

    • 7.3 Online Pharmacy

      • 7.3.1 Key market trends, growth factors and opportunities

      • 7.3.2 Market size and forecast, by region

      • 7.3.3 Market analysis by country

    • 7.4 Retail Pharmacy

      • 7.4.1 Key market trends, growth factors and opportunities

      • 7.4.2 Market size and forecast, by region

      • 7.4.3 Market analysis by country

  • CHAPTER 8: HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY REGION

    • 8.1 Overview

      • 8.1.1 Market size and forecast

    • 8.2 North America

      • 8.2.1 Key trends and opportunities

      • 8.2.2 North America Market size and forecast, by Treatment

      • 8.2.3 North America Market size and forecast, by Type

      • 8.2.4 North America Market size and forecast, by Route of administration

      • 8.2.5 North America Market size and forecast, by Distribution channel

      • 8.2.6 North America Market size and forecast, by country

        • 8.2.6.1 U.S.
          • 8.2.6.1.1 Market size and forecast, by Treatment
          • 8.2.6.1.2 Market size and forecast, by Type
          • 8.2.6.1.3 Market size and forecast, by Route of administration
          • 8.2.6.1.4 Market size and forecast, by Distribution channel
        • 8.2.6.2 Canada
          • 8.2.6.2.1 Market size and forecast, by Treatment
          • 8.2.6.2.2 Market size and forecast, by Type
          • 8.2.6.2.3 Market size and forecast, by Route of administration
          • 8.2.6.2.4 Market size and forecast, by Distribution channel
        • 8.2.6.3 Mexico
          • 8.2.6.3.1 Market size and forecast, by Treatment
          • 8.2.6.3.2 Market size and forecast, by Type
          • 8.2.6.3.3 Market size and forecast, by Route of administration
          • 8.2.6.3.4 Market size and forecast, by Distribution channel
    • 8.3 Europe

      • 8.3.1 Key trends and opportunities

      • 8.3.2 Europe Market size and forecast, by Treatment

      • 8.3.3 Europe Market size and forecast, by Type

      • 8.3.4 Europe Market size and forecast, by Route of administration

      • 8.3.5 Europe Market size and forecast, by Distribution channel

      • 8.3.6 Europe Market size and forecast, by country

        • 8.3.6.1 Germany
          • 8.3.6.1.1 Market size and forecast, by Treatment
          • 8.3.6.1.2 Market size and forecast, by Type
          • 8.3.6.1.3 Market size and forecast, by Route of administration
          • 8.3.6.1.4 Market size and forecast, by Distribution channel
        • 8.3.6.2 France
          • 8.3.6.2.1 Market size and forecast, by Treatment
          • 8.3.6.2.2 Market size and forecast, by Type
          • 8.3.6.2.3 Market size and forecast, by Route of administration
          • 8.3.6.2.4 Market size and forecast, by Distribution channel
        • 8.3.6.3 U.K.
          • 8.3.6.3.1 Market size and forecast, by Treatment
          • 8.3.6.3.2 Market size and forecast, by Type
          • 8.3.6.3.3 Market size and forecast, by Route of administration
          • 8.3.6.3.4 Market size and forecast, by Distribution channel
        • 8.3.6.4 Italy
          • 8.3.6.4.1 Market size and forecast, by Treatment
          • 8.3.6.4.2 Market size and forecast, by Type
          • 8.3.6.4.3 Market size and forecast, by Route of administration
          • 8.3.6.4.4 Market size and forecast, by Distribution channel
        • 8.3.6.5 Spain
          • 8.3.6.5.1 Market size and forecast, by Treatment
          • 8.3.6.5.2 Market size and forecast, by Type
          • 8.3.6.5.3 Market size and forecast, by Route of administration
          • 8.3.6.5.4 Market size and forecast, by Distribution channel
        • 8.3.6.6 Rest of Europe
          • 8.3.6.6.1 Market size and forecast, by Treatment
          • 8.3.6.6.2 Market size and forecast, by Type
          • 8.3.6.6.3 Market size and forecast, by Route of administration
          • 8.3.6.6.4 Market size and forecast, by Distribution channel
    • 8.4 Asia-Pacific

      • 8.4.1 Key trends and opportunities

      • 8.4.2 Asia-Pacific Market size and forecast, by Treatment

      • 8.4.3 Asia-Pacific Market size and forecast, by Type

      • 8.4.4 Asia-Pacific Market size and forecast, by Route of administration

      • 8.4.5 Asia-Pacific Market size and forecast, by Distribution channel

      • 8.4.6 Asia-Pacific Market size and forecast, by country

        • 8.4.6.1 China
          • 8.4.6.1.1 Market size and forecast, by Treatment
          • 8.4.6.1.2 Market size and forecast, by Type
          • 8.4.6.1.3 Market size and forecast, by Route of administration
          • 8.4.6.1.4 Market size and forecast, by Distribution channel
        • 8.4.6.2 Japan
          • 8.4.6.2.1 Market size and forecast, by Treatment
          • 8.4.6.2.2 Market size and forecast, by Type
          • 8.4.6.2.3 Market size and forecast, by Route of administration
          • 8.4.6.2.4 Market size and forecast, by Distribution channel
        • 8.4.6.3 India
          • 8.4.6.3.1 Market size and forecast, by Treatment
          • 8.4.6.3.2 Market size and forecast, by Type
          • 8.4.6.3.3 Market size and forecast, by Route of administration
          • 8.4.6.3.4 Market size and forecast, by Distribution channel
        • 8.4.6.4 Australia
          • 8.4.6.4.1 Market size and forecast, by Treatment
          • 8.4.6.4.2 Market size and forecast, by Type
          • 8.4.6.4.3 Market size and forecast, by Route of administration
          • 8.4.6.4.4 Market size and forecast, by Distribution channel
        • 8.4.6.5 South Korea
          • 8.4.6.5.1 Market size and forecast, by Treatment
          • 8.4.6.5.2 Market size and forecast, by Type
          • 8.4.6.5.3 Market size and forecast, by Route of administration
          • 8.4.6.5.4 Market size and forecast, by Distribution channel
        • 8.4.6.6 Rest of Asia-Pacific
          • 8.4.6.6.1 Market size and forecast, by Treatment
          • 8.4.6.6.2 Market size and forecast, by Type
          • 8.4.6.6.3 Market size and forecast, by Route of administration
          • 8.4.6.6.4 Market size and forecast, by Distribution channel
    • 8.5 LAMEA

      • 8.5.1 Key trends and opportunities

      • 8.5.2 LAMEA Market size and forecast, by Treatment

      • 8.5.3 LAMEA Market size and forecast, by Type

      • 8.5.4 LAMEA Market size and forecast, by Route of administration

      • 8.5.5 LAMEA Market size and forecast, by Distribution channel

      • 8.5.6 LAMEA Market size and forecast, by country

        • 8.5.6.1 Brazil
          • 8.5.6.1.1 Market size and forecast, by Treatment
          • 8.5.6.1.2 Market size and forecast, by Type
          • 8.5.6.1.3 Market size and forecast, by Route of administration
          • 8.5.6.1.4 Market size and forecast, by Distribution channel
        • 8.5.6.2 Saudi Arabia
          • 8.5.6.2.1 Market size and forecast, by Treatment
          • 8.5.6.2.2 Market size and forecast, by Type
          • 8.5.6.2.3 Market size and forecast, by Route of administration
          • 8.5.6.2.4 Market size and forecast, by Distribution channel
        • 8.5.6.3 South Africa
          • 8.5.6.3.1 Market size and forecast, by Treatment
          • 8.5.6.3.2 Market size and forecast, by Type
          • 8.5.6.3.3 Market size and forecast, by Route of administration
          • 8.5.6.3.4 Market size and forecast, by Distribution channel
        • 8.5.6.4 Rest of LAMEA
          • 8.5.6.4.1 Market size and forecast, by Treatment
          • 8.5.6.4.2 Market size and forecast, by Type
          • 8.5.6.4.3 Market size and forecast, by Route of administration
          • 8.5.6.4.4 Market size and forecast, by Distribution channel
  • CHAPTER 9: COMPANY LANDSCAPE

    • 9.1. Introduction

    • 9.2. Top winning strategies

    • 9.3. Product Mapping of Top 10 Player

    • 9.4. Competitive Dashboard

    • 9.5. Competitive Heatmap

    • 9.6. Key developments

  • CHAPTER 10: COMPANY PROFILES

    • 10.1 ALK Abello A S

      • 10.1.1 Company overview

      • 10.1.2 Company snapshot

      • 10.1.3 Operating business segments

      • 10.1.4 Product portfolio

      • 10.1.5 Business performance

      • 10.1.6 Key strategic moves and developments

    • 10.2 Allergy Therapeutics PLC

      • 10.2.1 Company overview

      • 10.2.2 Company snapshot

      • 10.2.3 Operating business segments

      • 10.2.4 Product portfolio

      • 10.2.5 Business performance

      • 10.2.6 Key strategic moves and developments

    • 10.3 Bayer AG

      • 10.3.1 Company overview

      • 10.3.2 Company snapshot

      • 10.3.3 Operating business segments

      • 10.3.4 Product portfolio

      • 10.3.5 Business performance

      • 10.3.6 Key strategic moves and developments

    • 10.4 Catalent Pharma Solutions Limited

      • 10.4.1 Company overview

      • 10.4.2 Company snapshot

      • 10.4.3 Operating business segments

      • 10.4.4 Product portfolio

      • 10.4.5 Business performance

      • 10.4.6 Key strategic moves and developments

    • 10.5 GlaxoSmithKline plc.

      • 10.5.1 Company overview

      • 10.5.2 Company snapshot

      • 10.5.3 Operating business segments

      • 10.5.4 Product portfolio

      • 10.5.5 Business performance

      • 10.5.6 Key strategic moves and developments

    • 10.6 johnson and johnson md&d

      • 10.6.1 Company overview

      • 10.6.2 Company snapshot

      • 10.6.3 Operating business segments

      • 10.6.4 Product portfolio

      • 10.6.5 Business performance

      • 10.6.6 Key strategic moves and developments

    • 10.7 Merz Pharma GmbH an Co. KGaA

      • 10.7.1 Company overview

      • 10.7.2 Company snapshot

      • 10.7.3 Operating business segments

      • 10.7.4 Product portfolio

      • 10.7.5 Business performance

      • 10.7.6 Key strategic moves and developments

    • 10.8 Sanofi

      • 10.8.1 Company overview

      • 10.8.2 Company snapshot

      • 10.8.3 Operating business segments

      • 10.8.4 Product portfolio

      • 10.8.5 Business performance

      • 10.8.6 Key strategic moves and developments

    • 10.9 Seqirus UK Limited

      • 10.9.1 Company overview

      • 10.9.2 Company snapshot

      • 10.9.3 Operating business segments

      • 10.9.4 Product portfolio

      • 10.9.5 Business performance

      • 10.9.6 Key strategic moves and developments

    • 10.10 Shionogi and Co. Ltd.

      • 10.10.1 Company overview

      • 10.10.2 Company snapshot

      • 10.10.3 Operating business segments

      • 10.10.4 Product portfolio

      • 10.10.5 Business performance

      • 10.10.6 Key strategic moves and developments

  • LIST OF TABLES

    • TABLE 1. GLOBAL HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 2. HOUSE DUST MITE ALLERGY TREATMENT MARKET SIZE, FOR ANTIHISTAMINE, BY REGION, 2021-2031 ($MILLION)
    • TABLE 3. HOUSE DUST MITE ALLERGY TREATMENT MARKET FOR ANTIHISTAMINE, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 4. HOUSE DUST MITE ALLERGY TREATMENT MARKET SIZE, FOR IMMUNOTHERAPY, BY REGION, 2021-2031 ($MILLION)
    • TABLE 5. HOUSE DUST MITE ALLERGY TREATMENT MARKET FOR IMMUNOTHERAPY, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 6. HOUSE DUST MITE ALLERGY TREATMENT MARKET SIZE, FOR OTHER, BY REGION, 2021-2031 ($MILLION)
    • TABLE 7. HOUSE DUST MITE ALLERGY TREATMENT MARKET FOR OTHER, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 8. GLOBAL HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 9. HOUSE DUST MITE ALLERGY TREATMENT MARKET SIZE, FOR PRESCRIPTION BASED DRUGS, BY REGION, 2021-2031 ($MILLION)
    • TABLE 10. HOUSE DUST MITE ALLERGY TREATMENT MARKET FOR PRESCRIPTION BASED DRUGS, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 11. HOUSE DUST MITE ALLERGY TREATMENT MARKET SIZE, FOR OVER THE COUNTER DRUGS, BY REGION, 2021-2031 ($MILLION)
    • TABLE 12. HOUSE DUST MITE ALLERGY TREATMENT MARKET FOR OVER THE COUNTER DRUGS, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 13. GLOBAL HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 14. HOUSE DUST MITE ALLERGY TREATMENT MARKET SIZE, FOR ORAL MEDICATION, BY REGION, 2021-2031 ($MILLION)
    • TABLE 15. HOUSE DUST MITE ALLERGY TREATMENT MARKET FOR ORAL MEDICATION, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 16. HOUSE DUST MITE ALLERGY TREATMENT MARKET SIZE, FOR NASAL ADMINISTRATION, BY REGION, 2021-2031 ($MILLION)
    • TABLE 17. HOUSE DUST MITE ALLERGY TREATMENT MARKET FOR NASAL ADMINISTRATION, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 18. GLOBAL HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 19. HOUSE DUST MITE ALLERGY TREATMENT MARKET SIZE, FOR HOSPITAL PHARMACY, BY REGION, 2021-2031 ($MILLION)
    • TABLE 20. HOUSE DUST MITE ALLERGY TREATMENT MARKET FOR HOSPITAL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 21. HOUSE DUST MITE ALLERGY TREATMENT MARKET SIZE, FOR ONLINE PHARMACY, BY REGION, 2021-2031 ($MILLION)
    • TABLE 22. HOUSE DUST MITE ALLERGY TREATMENT MARKET FOR ONLINE PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 23. HOUSE DUST MITE ALLERGY TREATMENT MARKET SIZE, FOR RETAIL PHARMACY, BY REGION, 2021-2031 ($MILLION)
    • TABLE 24. HOUSE DUST MITE ALLERGY TREATMENT MARKET FOR RETAIL PHARMACY, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 25. HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
    • TABLE 26. NORTH AMERICA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 27. NORTH AMERICA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 28. NORTH AMERICA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 29. NORTH AMERICA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 30. NORTH AMERICA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 31. U.S. HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 32. U.S. HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 33. U.S. HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 34. U.S. HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 35. CANADA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 36. CANADA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 37. CANADA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 38. CANADA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 39. MEXICO HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 40. MEXICO HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 41. MEXICO HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 42. MEXICO HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 43. EUROPE HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 44. EUROPE HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 45. EUROPE HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 46. EUROPE HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 47. EUROPE HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 48. GERMANY HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 49. GERMANY HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 50. GERMANY HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 51. GERMANY HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 52. FRANCE HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 53. FRANCE HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 54. FRANCE HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 55. FRANCE HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 56. U.K. HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 57. U.K. HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 58. U.K. HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 59. U.K. HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 60. ITALY HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 61. ITALY HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 62. ITALY HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 63. ITALY HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 64. SPAIN HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 65. SPAIN HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 66. SPAIN HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 67. SPAIN HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 68. REST OF EUROPE HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 69. REST OF EUROPE HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 70. REST OF EUROPE HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 71. REST OF EUROPE HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 72. ASIA-PACIFIC HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 73. ASIA-PACIFIC HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 74. ASIA-PACIFIC HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 75. ASIA-PACIFIC HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 76. ASIA-PACIFIC HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 77. CHINA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 78. CHINA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 79. CHINA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 80. CHINA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 81. JAPAN HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 82. JAPAN HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 83. JAPAN HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 84. JAPAN HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 85. INDIA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 86. INDIA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 87. INDIA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 88. INDIA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 89. AUSTRALIA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 90. AUSTRALIA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 91. AUSTRALIA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 92. AUSTRALIA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 93. SOUTH KOREA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 94. SOUTH KOREA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 95. SOUTH KOREA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 96. SOUTH KOREA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 97. REST OF ASIA-PACIFIC HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 98. REST OF ASIA-PACIFIC HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 99. REST OF ASIA-PACIFIC HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 100. REST OF ASIA-PACIFIC HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 101. LAMEA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 102. LAMEA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 103. LAMEA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 104. LAMEA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 105. LAMEA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
    • TABLE 106. BRAZIL HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 107. BRAZIL HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 108. BRAZIL HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 109. BRAZIL HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 110. SAUDI ARABIA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 111. SAUDI ARABIA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 112. SAUDI ARABIA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 113. SAUDI ARABIA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 114. SOUTH AFRICA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 115. SOUTH AFRICA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 116. SOUTH AFRICA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 117. SOUTH AFRICA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 118. REST OF LAMEA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TREATMENT, 2021-2031 ($MILLION)
    • TABLE 119. REST OF LAMEA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
    • TABLE 120. REST OF LAMEA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
    • TABLE 121. REST OF LAMEA HOUSE DUST MITE ALLERGY TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
    • TABLE 122.ALK ABELLO A S: COMPANY SNAPSHOT
    • TABLE 123.ALK ABELLO A S: OPERATING SEGMENTS
    • TABLE 124.ALK ABELLO A S: PRODUCT PORTFOLIO
    • TABLE 125.ALK ABELLO A S: NET SALES,
    • TABLE 126.ALK ABELLO A S: KEY STRATERGIES
    • TABLE 127.ALLERGY THERAPEUTICS PLC: COMPANY SNAPSHOT
    • TABLE 128.ALLERGY THERAPEUTICS PLC: OPERATING SEGMENTS
    • TABLE 129.ALLERGY THERAPEUTICS PLC: PRODUCT PORTFOLIO
    • TABLE 130.ALLERGY THERAPEUTICS PLC: NET SALES,
    • TABLE 131.ALLERGY THERAPEUTICS PLC: KEY STRATERGIES
    • TABLE 132.BAYER AG: COMPANY SNAPSHOT
    • TABLE 133.BAYER AG: OPERATING SEGMENTS
    • TABLE 134.BAYER AG: PRODUCT PORTFOLIO
    • TABLE 135.BAYER AG: NET SALES,
    • TABLE 136.BAYER AG: KEY STRATERGIES
    • TABLE 137.CATALENT PHARMA SOLUTIONS LIMITED: COMPANY SNAPSHOT
    • TABLE 138.CATALENT PHARMA SOLUTIONS LIMITED: OPERATING SEGMENTS
    • TABLE 139.CATALENT PHARMA SOLUTIONS LIMITED: PRODUCT PORTFOLIO
    • TABLE 140.CATALENT PHARMA SOLUTIONS LIMITED: NET SALES,
    • TABLE 141.CATALENT PHARMA SOLUTIONS LIMITED: KEY STRATERGIES
    • TABLE 142.GLAXOSMITHKLINE PLC.: COMPANY SNAPSHOT
    • TABLE 143.GLAXOSMITHKLINE PLC.: OPERATING SEGMENTS
    • TABLE 144.GLAXOSMITHKLINE PLC.: PRODUCT PORTFOLIO
    • TABLE 145.GLAXOSMITHKLINE PLC.: NET SALES,
    • TABLE 146.GLAXOSMITHKLINE PLC.: KEY STRATERGIES
    • TABLE 147.JOHNSON AND JOHNSON MD&D: COMPANY SNAPSHOT
    • TABLE 148.JOHNSON AND JOHNSON MD&D: OPERATING SEGMENTS
    • TABLE 149.JOHNSON AND JOHNSON MD&D: PRODUCT PORTFOLIO
    • TABLE 150.JOHNSON AND JOHNSON MD&D: NET SALES,
    • TABLE 151.JOHNSON AND JOHNSON MD&D: KEY STRATERGIES
    • TABLE 152.MERZ PHARMA GMBH AN CO. KGAA: COMPANY SNAPSHOT
    • TABLE 153.MERZ PHARMA GMBH AN CO. KGAA: OPERATING SEGMENTS
    • TABLE 154.MERZ PHARMA GMBH AN CO. KGAA: PRODUCT PORTFOLIO
    • TABLE 155.MERZ PHARMA GMBH AN CO. KGAA: NET SALES,
    • TABLE 156.MERZ PHARMA GMBH AN CO. KGAA: KEY STRATERGIES
    • TABLE 157.SANOFI: COMPANY SNAPSHOT
    • TABLE 158.SANOFI: OPERATING SEGMENTS
    • TABLE 159.SANOFI: PRODUCT PORTFOLIO
    • TABLE 160.SANOFI: NET SALES,
    • TABLE 161.SANOFI: KEY STRATERGIES
    • TABLE 162.SEQIRUS UK LIMITED: COMPANY SNAPSHOT
    • TABLE 163.SEQIRUS UK LIMITED: OPERATING SEGMENTS
    • TABLE 164.SEQIRUS UK LIMITED: PRODUCT PORTFOLIO
    • TABLE 165.SEQIRUS UK LIMITED: NET SALES,
    • TABLE 166.SEQIRUS UK LIMITED: KEY STRATERGIES
    • TABLE 167.SHIONOGI AND CO. LTD.: COMPANY SNAPSHOT
    • TABLE 168.SHIONOGI AND CO. LTD.: OPERATING SEGMENTS
    • TABLE 169.SHIONOGI AND CO. LTD.: PRODUCT PORTFOLIO
    • TABLE 170.SHIONOGI AND CO. LTD.: NET SALES,
    • TABLE 171.SHIONOGI AND CO. LTD.: KEY STRATERGIES
  • LIST OF FIGURES

    • FIGURE 1.HOUSE DUST MITE ALLERGY TREATMENT MARKET SEGMENTATION
    • FIGURE 2.HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031
    • FIGURE 3.HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031
    • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
    • FIGURE 5.PORTER FIVE-1
    • FIGURE 6.PORTER FIVE-2
    • FIGURE 7.PORTER FIVE-3
    • FIGURE 8.PORTER FIVE-4
    • FIGURE 9.PORTER FIVE-5
    • FIGURE 10.TOP PLAYER POSITIONING
    • FIGURE 11.HOUSE DUST MITE ALLERGY TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
    • FIGURE 12.HOUSE DUST MITE ALLERGY TREATMENT MARKET,BY TREATMENT,2021(%)
    • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANTIHISTAMINE HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031(%)
    • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF IMMUNOTHERAPY HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031(%)
    • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHER HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031(%)
    • FIGURE 16.HOUSE DUST MITE ALLERGY TREATMENT MARKET,BY TYPE,2021(%)
    • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF PRESCRIPTION BASED DRUGS HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031(%)
    • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF OVER THE COUNTER DRUGS HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031(%)
    • FIGURE 19.HOUSE DUST MITE ALLERGY TREATMENT MARKET,BY ROUTE OF ADMINISTRATION,2021(%)
    • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF ORAL MEDICATION HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031(%)
    • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF NASAL ADMINISTRATION HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031(%)
    • FIGURE 22.HOUSE DUST MITE ALLERGY TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
    • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACY HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031(%)
    • FIGURE 24.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACY HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031(%)
    • FIGURE 25.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACY HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031(%)
    • FIGURE 26.HOUSE DUST MITE ALLERGY TREATMENT MARKET BY REGION,2021
    • FIGURE 27.U.S. HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 28.CANADA HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 29.MEXICO HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 30.GERMANY HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 31.FRANCE HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 32.U.K. HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 33.ITALY HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 34.SPAIN HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 35.REST OF EUROPE HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 36.CHINA HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 37.JAPAN HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 38.INDIA HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 39.AUSTRALIA HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 40.SOUTH KOREA HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 41.REST OF ASIA-PACIFIC HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 42.BRAZIL HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 43.SAUDI ARABIA HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 44.SOUTH AFRICA HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 45.REST OF LAMEA HOUSE DUST MITE ALLERGY TREATMENT MARKET,2021-2031($MILLION)
    • FIGURE 46. TOP WINNING STRATEGIES, BY YEAR
    • FIGURE 47. TOP WINNING STRATEGIES, BY DEVELOPMENT
    • FIGURE 48. TOP WINNING STRATEGIES, BY COMPANY
    • FIGURE 49.PRODUCT MAPPING OF TOP 10 PLAYERS
    • FIGURE 50.COMPETITIVE DASHBOARD
    • FIGURE 51.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
    • FIGURE 52.ALK ABELLO A S.: NET SALES ,($MILLION)
    • FIGURE 53.ALLERGY THERAPEUTICS PLC.: NET SALES ,($MILLION)
    • FIGURE 54.BAYER AG.: NET SALES ,($MILLION)
    • FIGURE 55.CATALENT PHARMA SOLUTIONS LIMITED.: NET SALES ,($MILLION)
    • FIGURE 56.GLAXOSMITHKLINE PLC..: NET SALES ,($MILLION)
    • FIGURE 57.JOHNSON AND JOHNSON MD&D.: NET SALES ,($MILLION)
    • FIGURE 58.MERZ PHARMA GMBH AN CO. KGAA.: NET SALES ,($MILLION)
    • FIGURE 59.SANOFI.: NET SALES ,($MILLION)
    • FIGURE 60.SEQIRUS UK LIMITED.: NET SALES ,($MILLION)
    • FIGURE 61.SHIONOGI AND CO. LTD..: NET SALES ,($MILLION)

 
 

According to the insights of the CXOs of top-level companies, antihistamines, immunotherapies, corticosteroids, and nasal irrigations are the common treatment approaches for house dust mite allergy. For instance, in May 2021, the Glenmark Pharmaceutical Ltd., a global pharmaceutical companies, announced the launch of Ryaltris AZ nasal spray, which is used for the treatment of allergic rhinitis. Allergic rhinitis is one of the most common symptoms associated with house dust mite allergy reaction allergy. Moreover, in September 2020, the U.S Food and Drug Administration (FDA) announced the approval to supplement the Biologics License Application (BLA) under section 351(a) of the Public Health Service Act for house dust mite allergen extract

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of house dust mite allergy treatment market is $1,481.2 million in 2021.

A. The forecast period in the report is from 2022 to 2031

A. The market value of house dust mite allergy treatment market in 2022 was $1,676.7 million

A. Yes, house dust mite allergy treatment companies are profiled in the report

A. The top companies that hold the market share in house dust mite allergy treatment market are ALK-Abello A/S, Allergy Therapeutics PLC, Bayer AG, Catalent Pharma Solutions Limited, GlaxoSmithKline Plc., Johnson and Johnson, Merz Pharma GmbH an Co. KGaA, Sanofi, Seqirus UK Limited, and Shionogi & Co. Ltd

A. Asia-Pacific is expected to register highest CAGR of 14.4% from 2022 to 2031, owing to increase in prevalence of house dust mite allergy diseases, rise in awareness about spreading knowledge regarding allergens, surge in healthcare expenditure, and rise in adoption of immunotherapy drugs for the treatment of house dust mite allergies

A. The key trends in the house dust mite allergy treatment market are increase in prevalence of allergic diseases associated with house dust mites, rise in demand for immunological products, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments, and rise in R&D activities for manufacturing of anti-allergy drugs

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Sample
RELATED TAGS

Purchase Full Report of
House Dust Mite Allergy Treatment Market

Start reading instantly.
This Report and over 67,404+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Jun 2023 - Jun 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2023 - Jun 2024)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2023 - Jun 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2023 - Jun 2024)
  • Enterprise
    License/PDF

  • $10,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Jun 2023 - Jun 2024)
  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers